康拓医疗(688314) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥80,772,405.35, a decrease of 6.92% compared to the same period last year[4] - The total profit for the period was ¥24,365,076.68, reflecting a decline of 26.31% year-on-year[4] - The net profit attributable to shareholders was ¥21,716,516.65, down 22.22% from the previous year[4] - Total operating revenue for the first three quarters of 2025 reached ¥251,088,755.11, an increase of 4.1% compared to ¥240,117,907.83 in the same period of 2024[19] - Total operating costs for the first three quarters of 2025 were ¥156,565,067.29, up from ¥148,313,124.73 in 2024, reflecting a year-over-year increase of 5.5%[19] - Net profit for the first three quarters of 2025 was ¥75,906,135.43, slightly down from ¥76,006,339.62 in 2024, indicating a decrease of 0.1%[20] - The company reported a total profit of ¥89,724,401.40 for the first three quarters of 2025, compared to ¥92,332,439.71 in 2024, reflecting a decrease of 2.8%[20] Research and Development - Research and development expenses totaled ¥10,114,843.75, an increase of 23.61% compared to the same quarter last year, representing 12.52% of operating revenue[5] - Research and development expenses for the first three quarters of 2025 were ¥17,980,206.24, up from ¥16,399,769.03 in 2024, representing an increase of 9.7%[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥790,933,245.95, an increase of 5.85% from the end of the previous year[5] - The equity attributable to shareholders increased by 8.29% year-on-year, reaching ¥688,268,864.98[5] - The company's total liabilities decreased to ¥100,587,268.91 in 2025 from ¥109,374,780.75 in 2024, a reduction of approximately 8.1%[17] - The total equity attributable to shareholders increased to ¥688,268,864.98 in 2025, compared to ¥635,577,490.21 in 2024, marking an increase of about 8.3%[17] Cash Flow - The net cash flow from operating activities was ¥23,893,689.92, down 29.17% year-on-year[5] - The company’s cash flow from operating activities for the first three quarters of 2025 showed a positive trend, although specific figures were not disclosed in the provided data[21] - In the first three quarters of 2025, the cash inflow from operating activities was CNY 287,099,764.83, a slight decrease of 0.65% compared to CNY 288,963,805.42 in the same period of 2024[22] - The net cash flow from operating activities decreased to CNY 86,083,545.57, down 21.5% from CNY 109,654,732.43 year-on-year[22] - Cash inflow from investment activities totaled CNY 629,164,479.21, significantly increasing by 81.1% from CNY 347,020,186.10 in the previous year[23] - The net cash flow from investment activities was negative at CNY -193,046,531.01, worsening from CNY -151,796,237.78 in the same period last year[23] - Cash outflow from financing activities was CNY 33,577,694.13, compared to CNY 29,942,653.10 in the previous year, reflecting an increase of 8.7%[23] - The ending balance of cash and cash equivalents decreased to CNY 237,174,086.51, down 21.6% from CNY 302,407,498.71 at the end of the same period last year[23] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 5,879[11] - The largest shareholder, Hu Liren, holds 39,545,788 shares, representing 48.68% of total shares[11] Current Assets - Total current assets as of September 30, 2025, amount to ¥422,128,968.67, slightly up from ¥418,250,595.94 at the end of 2024[15] - Cash and cash equivalents decreased to ¥237,963,156.13 from ¥378,532,413.99[15] - Accounts receivable increased to ¥8,893,422.12 from ¥5,916,765.08, indicating a growth of 50.5%[15] - Inventory increased to ¥30,934,238.91 from ¥24,750,588.76, reflecting a rise of 24.9%[15] - Non-current assets total ¥368,804,277.28, up from ¥328,972,266.97[16] - Total assets increased to ¥790,933,245.95 from ¥747,222,862.91[16] - Current liabilities include accounts payable of ¥26,140,856.99, slightly up from ¥25,845,698.39[16] - The company has no short-term borrowings reported as of September 30, 2025[16] Other Information - The company reported a total of ¥195,239.57 in government subsidies recognized during the period, contributing positively to the financial results[7] - The company has not disclosed any significant new product developments or market expansion strategies in this report[10] - The company has not reported any net profit from mergers under common control for the current or previous periods, indicating no impact from such activities on the financial results[21] - The company experienced a negative impact of CNY -28,578.29 from exchange rate fluctuations on cash and cash equivalents[23]